The proto-oncogene KRAS is mutated in a wide array of human cancers, most of which are aggressive and respond poorly to standard therapies. Although the identification of specific oncogenes has led to the development of clinically effective, molecularly targeted therapies in some cases, KRAS has remained refractory to this approach. A complementary strategy for targeting KRAS is to identify gene products that, when inhibited, result in cell death only in the presence of an oncogenic allele 1,2 . Here we have used systematic RNA interference to detect synthetic lethal partners of oncogenic KRAS and found that the non-canonical IkB kinase TBK1 was selectively essential in cells that contain mutant KRAS. Suppression of TBK1 induced apoptosis specifically in human cancer cell lines that depend on oncogenic KRAS expression. In these cells, TBK1 activated NF-kB anti-apoptotic signals involving c-Rel and BCL-XL (also known as BCL2L1) that were essential for survival, providing mechanistic insights into this synthetic lethal interaction. These observations indicate that TBK1 and NF-kB signalling are essential in KRAS mutant tumours, and establish a general approach for the rational identification of co-dependent pathways in cancer.
To identify essential genes in human malignant and non-transformed cell lines, we performed arrayed format RNA interference (RNAi) screens in 19 cell lines (Supplementary Table 1 and Supplementary Fig. 1 ) using a short hairpin RNA (shRNA) library targeting kinases, phosphatases and oncogenes 3 . We then used two methods to find genes that were selectively required in cells expressing oncogenic KRAS. First, we used a class-discrimination feature selection method ( Fig. 1a ) in which normalized B-scores 4 for each cell line were analysed using a t-test statistic 5 to identify the top 250 (5%) shRNAs that distinguished between cell lines that contained mutant or wild-type KRAS. We focused on genes in which suppression by at least two shRNAs selectively impaired the proliferation/viability of KRAS mutant cells and identified KRAS itself (Supplementary Tables 2  and 3 and Supplementary Fig. 2a, b) .
In parallel, we used RNAi gene enrichment ranking (RIGER) 6 -a statistical approach that does not rely on arbitrary thresholds-to rank-order candidate KRAS synthetic lethal genes (Fig. 1b ). RIGER considers all shRNAs for a gene as a 'hairpin set', similar to 'gene sets' in gene set enrichment analysis (GSEA) 7 , and provides a normalized enrichment score (NES) for each gene with respect to a specific classification. Using the mutant versus wild-type KRAS class distinction as the classification feature, we ranked candidate KRAS synthetic lethal partners by NES and selected the top 40 genes, which included 12 of the 17 candidates identified by the individual shRNA-based analysis (Fig. 1b, c and Supplementary Tables 2-4) . 
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Cell viability (B-score) To validate the 45 candidates identified by these two approaches, we performed a secondary screen on an independent panel of mutant or wild-type KRAS lung adenocarcinoma cell lines (Supplementary Figs 3a, b and 4a, b). Proliferation/viability data for each shRNA was normalized to the median value of 20 control shRNAs. Using the t-test statistic to rank shRNAs that selectively impaired proliferation/ viability in mutant KRAS cells, we identified a significantly enriched subset of candidate shRNAs (P # 0.0002) ( Supplementary Fig. 5a ). Three KRAS-specific shRNAs were among the top four shRNAs that distinguished between KRAS mutant and wild-type cell lines (Supplementary Figs 4a, c and 5b). Using RIGER to rank candidate genes with respect to KRAS-selective lethality, we identified KRAS and TBK1 as the most significant genes (false discovery rate (FDR) of 0.04 and 0.18, respectively) ( Fig. 1d) . Although the secondary screen identified other potential KRAS synthetic lethal genes, we focused on TBK1 because it represented the top candidate after KRAS.
Indeed, we found that the two top-scoring shRNAs induced TBK1 suppression and substantial cell death in NCI-H23 cells (mutant KRAS) ( Fig. 2a ). To confirm these findings, we introduced KRASor TBK1-specific shRNAs into a third set of lung cancer cell lines ( Fig. 2b) , and observed a strong correlation between KRAS and TBK1 dependence, even in cell lines in which KRAS mutation status and dependence were decoupled. We also used an isogenic experimental model to isolate the genetic interaction between oncogenic KRAS and TBK1. Specifically, the expression of oncogenic KRAS in immortalized human lung epithelial cells (AALE-K cells) 8 rendered them dependent on both KRAS and TBK1 for survival, as compared to cells expressing a control vector (AALE-V cells) ( Fig. 2c ). When we suppressed TBK1 in A549 or NCI-H2009 (mutant KRAS) cells, tumour formation was inhibited, whereas the suppression of TBK1 had no effect on the tumorigenicity of NCI-H1437 or NCI-H1568 (wild-type KRAS) cells ( Fig. 2d ). These observations confirm that cancer cell lines that depend on oncogenic KRAS require TBK1 expression.
To determine whether the suppression of TBK1 in KRAS-dependent cells induced apoptosis, we found that, similar to shRNAs targeting KRAS itself ( Supplementary Fig. 4b ), TBK1-specific shRNAs provoked an increase in PARP cleavage ( Fig. 2e ) and TdT-mediated dUTP nick end labelling (TUNEL)-positive nuclei (P , 0.01) ( Fig. 2f and Supplementary Fig. 6a ) in NCI-H23 cells (mutant KRAS) but not in NCI-H1437 cells (wild-type KRAS). Suppression of mouse Tbk1 in cells derived from a KRAS-driven murine model of lung cancer (LKR-13 cells) 9 also induced apoptosis ( Supplementary Fig. 6b ).
KRAS activates several signalling pathways including those regulated by RAF kinases, phosphatidylinositol-3-OH kinases (PI(3)Ks) and RalGEFs (also known as RALGDSs). We found that the suppression of RAF1, BRAF or AKT1 failed to kill KRAS-dependent lung cancer cell lines selectively ( Fig. 2g and Supplementary Fig. 6c ). TBK1 suppression also failed to alter phosphorylated-p42/p44 MAP (mitogen-activated protein) kinase or phosphorylated-AKT levels ( Supplementary Fig. 6d ). In contrast, the suppression of RALB resulted in significant selective lethality in KRAS-dependent cell lines (P , 0.01, Fig. 2g ). Consistent with previous work linking RALB with TBK1 activation in the setting of tumour cell survival 10 , this observation suggested that RALB-TBK1 signalling was required in cells that depend on oncogenic KRAS. LETTERS TBK1 is a non-canonical IkB kinase that regulates innate immunity through the interferon and NF-kB pathways 11 , and is also a component of the exocyst complex 10 . To examine how TBK1 contributes to survival in KRAS-dependent cell lines, we performed transcriptional profiling on AALE cells expressing a control vector (AALE-V), oncogenic KRAS (AALE-K) or wild-type KRAS (AALE-K wild type). Using GSEA to identify gene sets from the Molecular Signatures Database (MSigDB-C2 v2) 7 that were enriched in AALE-K cells, we identified a previously described oncogenic RAS signature 12 as well as several NF-kB pathway activation signatures 13, 14 among the most significantly enriched gene sets (P # 4.5 3 10 27 , hypergeometric test) ( Fig. 3a and Supplementary Fig. 7a ). In contrast, we failed to detect enrichment of oncogenic RAS or NF-kB signatures in AALE-K wildtype cells (Fig. 3a) , indicating that the expression of oncogenic but not wild-type KRAS correlated with NF-kB signalling.
To extend these observations to patient-derived tumours, we analysed expression profiles from 128 lung adenocarcinomas 15, 16 for expression of the oncogenic RAS 12 , NF-kB 13, 14 and IRF3 (ref. 17) signatures as well as a KRAS-specific signature (AALE-K) composed of the genes most significantly induced in AALE-K relative to AALE-V cells. We found that most mutant KRAS tumours (14 out of 19) showed RAS signature activation and co-expression of the NF-kB signature (P # 1.3 3 10 215 , Spearman correlation test with Bonferroni adjustment) or the IKKe-regulated NF-kB gene subset (P # 0.008), but not the IRF3-regulated gene set (P # 0.18) (Fig. 3b ). These observations confirm that most lung cancers that contain mutant KRAS show evidence of RAS and NF-kB pathway activation, and suggest that a substantial fraction of KRAS mutant primary lung cancers may depend on TBK1 and NF-kB signalling for survival.
Consistent with recent work 18 , we also identified RAS and NF-kB signature co-activation in 30 out of 109 KRAS wild-type tumours (Fig. 3c ). These RAS and NF-kB signatures identified some but not all of the KRAS wild-type cell lines that showed KRAS dependence (Supplementary Table 1 and Fig. 2b ), suggesting that a subset of KRAS wild-type tumours depend on TBK1 and NF-kB signalling for survival. Further work will be necessary to determine whether such signatures will prove useful in predicting responsiveness to TBK1 inhibition.
Although TBK1 activates the interferon pathway through the regulation of IRF3 and IRF7 (refs 10, 11), we failed to observe increased expression of IRF3 target genes 17 ( Supplementary Fig. 7b ) or increased IRF3 nuclear translocation ( Supplementary Fig. 8a ) in AALE-K cells. In addition, the suppression of KRAS or TBK1 in KRAS mutant cancer cells downregulated specific genes within the NF-kB subset, including CCND1, BCL2 and IL8, but failed to alter the expression of known interferon-responsive genes, such as IFNB1 and RANTES (also known as CCL5) ( Supplementary Fig. 7c ). When we suppressed TBK1 in AALE-K cells, we observed that NF-kB signature components and several NF-kB targets, including the antiapoptotic gene BCL-XL, were among the most significantly downregulated genes (Fig. 3d ). These findings confirm the importance of the NF-kB pathway in promoting survival in the setting of oncogenic RAS 19 , and suggest that, distinct from its role in innate immunity, TBK1 preferentially activates NF-kB signalling in tumours dependent on oncogenic KRAS.
TBK1 has been reported to regulate the stability of IkB proteins 11 . When we examined cytoplasmic levels of IkB family members in AALE-K cells, we found reduced levels of IkBa (encoded by NFKBIA) and p105 (encoded by NFKB1) as compared to AALE-V cells ( Fig. 3e and Supplementary Fig. 8a, b) . Moreover, the suppression of TBK1 in AALE-K cells or KRAS-mutant NCI-H23 cells (Fig. 3e , f) returned levels to that observed in wild-type KRAS cells. The expression of the IkBa super-repressor (IKB-SR) 20 , which inhibits NF-kB activity, in AALE-K, AALE-V or cancer cell lines expressing mutant or wild-type KRAS induced cell death specifically in cells containing mutant KRAS ( Fig. 3g and Supplementary Fig. 9 ). These findings confirm that TBK1-driven NF-kB activity promotes the survival of cells that depend on mutant KRAS.
In the primary shRNA screen, we noted that one shRNA targeting the NF-kB family member c-Rel (also known as REL) scored as selectively lethal in KRAS mutant cells, albeit just below our pre-determined threshold. Suppression of c-Rel but not IRF3 selectively induced apoptosis in KRAS mutant cells (P # 0.001) ( Fig. 4a and Supplementary Fig.  10a ). Moreover, we found that the suppression of TBK1 in KRAS mutant cancer cells reduced the total and nuclear c-Rel levels ( Fig. 4b and Supplementary Fig. 10b ). Although TBK1 can phosphorylate c-Rel when overexpressed 21 , we failed to detect an interaction between TBK1 and c-Rel, but confirmed that endogenous c-Rel and p105 interact ( Supplementary Fig. 10c) 22 .
Because BCL-XL, a known c-Rel target 23 , was identified as a TBK1regulated gene in AALE-K cells (Fig. 3d) , we examined the expression of several anti-apoptotic genes after TBK1 suppression in KRASmutant cancer cells, and observed specific downregulation of BCL-XL in several cell lines ( Fig. 4b and Supplementary Fig. 10d ). Moreover, the overexpression of BCL-XL rescued apoptosis induced by KRAS or TBK1 suppression in NCI-H23 cells (Fig. 4c, d ) but did not significantly affect cell death induced by the suppression of BIRC5 (also known as survivin) ( Supplementary Fig. 11 ), confirming p105, c-Rel and BCL-XL as mediators of NF-kB survival signalling downstream of TBK1 and KRAS. We have identified TBK1 as a synthetic lethal partner of oncogenic KRAS. These findings link RALB-mediated activation of TBK1 (ref. 10) to the generation of specific NF-kB-regulated survival signals downstream of oncogenic KRAS. Furthermore, although studies testing the effects of inhibiting TBK1 or NF-kB signalling in established tumours are necessary, TBK1 and more generally NF-kB signalling may represent an alternative method of targeting oncogenic KRAS-driven cancers. Recently, STK33 and PLK1 were identified as KRAS synthetic lethal partners by the application of RNAi screening in paired KRAS mutant and wild-type cell lines 24, 25 . Both genes were also identified in our computational analyses ( Supplementary Tables 3 and 4 ), but like c-Rel, they fell below our initial threshold for secondary screening. We anticipate that the development of fully validated shRNA libraries, coupled with the interrogation of larger numbers of cell lines, will permit saturating genetic screens to identify synthetic lethal partners of KRAS as well as other oncogenes and tumour suppressor genes. More generally, this and other studies 6, [24] [25] [26] [27] [28] indicate that the application of these functional and analytical approaches will facilitate the comprehensive identification of functional co-dependencies in cancer.
METHODS SUMMARY
Large-scale, arrayed format RNAi screens to identify genes essential for proliferation/viability were performed as described 3, 14 . The effect of introducing each of the 5,002 shRNAs (targeting 957 genes) was determined in 19 cell lines, and normalized using the B-score metric 4 . Feature selection of shRNA B-score data was performed using the Comparative Marker Application Suite in GenePattern 5 and was independently analysed using RIGER analysis 6 to compute NESs for each gene. Secondary screen viability data was normalized using a percentage of the control statistic, given the biased nature of the candidate shRNA plate. Expression profiling was used to generate a signature that correlates with KRAS activation and implicated NF-kB signalling in cell lines and tumours dependent on KRAS. Regulation of NF-kB by TBK1 was shown using biochemical and cell biological approaches. Details of the analytical methods are provided in the Methods. 
METHODS
RNAi screens. Large-scale RNAi arrayed format screening was conducted using a subset of the Broad Institute RNAi Consortium (TRC) shRNA library targeting kinases, phosphatases and other cancer-related genes 3, 14 . shRNA designs and protocols for high throughout lentiviral production are available at http:// www.broad.mit.edu/rnai/trc/lib. Cells were seeded in quadruplicate 384-well plates on day 0, followed by infection with 8 mg ml 21 polybrene on day 1. Puromycin selection for duplicate plates (concentration individualized per cell line, most cell lines 2 mg ml 21 ) was started on day 2. An ATP-based luminescence assay (Cell-Titer Glo, Promega) was used to determine the cell number on day 6. Raw luminescence values from duplicate plates were averaged, and the ratio of puromycin-positive to -negative values was used to assess infection efficiency. Data was normalized using the B-score metric-a variant of the Z-score that uses the median absolute deviation to account for plate-to-plate variability-as well as a two-way median polish to minimize row/column effects 4 . After excluding shRNAs with low infection efficiency, B-score values from puromycin-positive and -negative replicates were averaged for each shRNA. shRNA B-score values were aligned for the 5,002 shRNAs tested in all 19 cell lines. The secondary screen was conducted using a percentage of control statistic instead of the B-score.
Hairpin-level analysis. The meta-analysis of RNAi screens was performed using complementary computational approaches. The first involved conversion of the shRNA B-score file into a .res file format for input into the Comparative Marker Selection application suite in GenePattern, along with a standard classification file to generate class distinctions 5 . This method uses class discrimination feature selection and ranks shRNA B-score data by the t-test statistic or the signal-tonoise ratio to account for the difference in means between the two classes as well as the standard deviation across samples. Specifically, the difference in mean viability scores induced by each shRNA in the KRAS mutant class versus the wildtype class was normalized to its standard deviation using a t-test, and shRNAs were ranked by the t-test score to determine for class selective effects. To convert shRNA data to candidate genes and to reduce the likelihood of off-target effects, the top 250 (5%) of distinguishing shRNAs in the mutant KRAS class were filtered to identify several shRNAs targeting the same gene. Only those genes for which at least one shRNA yielded a mean B score ,21 across the KRAS mutant class were considered. Furthermore, shRNAs with low infection efficiency in several cell lines were excluded from the analysis. RIGER analysis. Similar to gene sets for GSEA 7 , hairpin sets were defined as the groups of shRNAs representing a given target gene. Because the number of shRNAs in a hairpin set are relatively small compared with the number of genes, we used different input data normalization, enrichment statistics and output formats compared with GSEA. RIGER analysis consisted of the following steps:
(1) Pre-processing: the input was the same data set of B-scores analysed using the individual shRNA-based method. The B-score values for each cell line were standardized with respect to the median and maximum absolute deviation of the set of control shRNAs (directed against GFP, LacZ, RFP and luciferase) in the same cell line. This centred and rescaled the values in a sample-specific manner according to the behaviour of the control hairpins. After normalization, values below 23 and above 3 were truncated to 23 and 3, respectively, to reduce the effect of outliers, and were called normalized survival scores.
(2) Feature ranking: after pre-processing, each shRNA was assigned a 'differential survival score', which represented the difference in means of the normalized survival scores in the two phenotypic classes (for example, KRAS mutant versus wild type). The difference in means was used to emphasize the absolute magnitude of the survival differences and not only the profile 'shape'. Specifically, this favoured shRNAs with strong differential killing of cells over ones that exhibited weak differential killing of cells, but had perfect discrimination profiles inside classes. The differential survival scores were computed for all the 5,002 shRNAs and sorted from high to low scores.
(3) Calculation of enrichment scores: a given gene was assigned an enrichment score according to the distribution of differential survival scores of its shRNAs within the rank list of all shRNAs using a two-sample weighted 'Zhang C' statistic based on the likelihood ratio 29 . The Zhang C likelihood ratio statistic was used owing to its greater sensitivity and better empirical results in exploratory analyses with other data sets. We adapted this method to separate positive and negative enrichment contributions, and used a weighting factor based on the differential enrichment score, except for scores between 20.5 and 0.5, which were truncated to reduce the effects of shRNAs that weakly distinguished classes. The enrichment score obtained in this manner was representative of both the extremeness of the shRNA differential survival scores for a given gene and their consistency.
(4) Normalization of enrichment scores: because genes with different numbers of shRNAs were assigned enrichment scores on different scales, we normalized them before sorting the genes by using a null distribution generated by 1,000 random permutations of the locations of the shRNAs in the entire list. The normalization for negative enrichment scores was a rescaling by the absolute value of the mean of the negative values in the null distribution. This represented an effective way to place the enrichment scores on a common scale regardless of the number of shRNAs for each gene. The null distribution also provided nominal P values for each gene enrichment score.
(5) Generation of results: the analysis resulted in a list of genes sorted by their NESs, and a set of complementary estimates of statistical significance, such as nominal, family-wise and Bonferroni P values plus a FDR. A collection of dualvertical plots was used to demonstrate the shRNA differential survival scores for each gene (lines in blue) and NESs (lines in red). Vertical plots were arranged starting with the top gene (strongest negative NES) on the left. Secondary screen. Analysis of secondary screen data followed the same methodology except for the normalization of the cell proliferation/viability data. Twenty control shRNAs directed against RFP, LacZ and luciferase were screened in parallel with candidates. We normalized data for each shRNA in each cell line using the percentage of control statistic, dividing the raw data for each shRNA by the median of control shRNA values, and taking the log 10 of this number to scale values around zero. Because of the biased nature of the candidate shRNA plate, and because the number of control shRNAs was smaller in the secondary screen than the first, the calculation of the maximum absolute deviation was noisy and unreliable. No truncation was applied to the resulting values.
A larger set of 84 control shRNAs directed against GFP, RFP, LacZ and luciferase was also tested independently in all eight cell lines chosen for the secondary screen. We normalized data for each shRNA in each cell line by dividing the raw data for each control shRNA by the plate median and taking the log 10 of this number to scale values around zero. We used the t-test statistic to examine the KRAS mutant versus wild-type class distinction for this control plate relative to the candidate plate, restricting the analysis to shRNAs with strong effects on proliferation/viability (mutant KRAS class mean log percentage of control ,20.2, corresponding to ,37% viability impairment) ( Supplementary Fig.  5a ). We used the t-test statistic threshold that was achieved by the set of control shRNAs as the boundary to identify the top 25 shRNAs KRAS synthetic lethal shRNAs that scored on the candidate plate ( Supplementary Fig. 5b ) Gene expression profiling or GSEA. RNA was prepared from AALE cells expressing KRAS(G12V) or a control vector 6 days after infection and analysed using human U133A HTA Arrays (Affymetrix). GSEA was performed using gene sets from the Molecular Signatures Database (MSigDB-C2 v2) 7 . In brief, the method consists of the following steps: genes are first ranked in a list, L, by the correlation between their expression and the class distinction (for example, KRAS mutant versus wild type), using a suitable correlation metric. Given a defined set of genes S (for example, genes members of a signalling pathway, located in the same genomic region, sharing the same Gene Ontology category, and so on), the goal of GSEA is to determine whether the members of S are found at the top or bottom of the list, indicating that they associate with the phenotypic distinction, rather than being distributed uniformly or randomly across the list. Next, to evaluate this degree of 'enrichment', an enrichment score is calculated to quantify the degree to which a set S is over-represented at the top or bottom of the entire ranked list L. After calculation of the scores for a collection of gene sets, an empirical phenotype-based permutation test procedure is used to estimate P values. The permutation of class labels preserves gene-gene correlations and provides an assessment of significance that is more reflective of the underlying biology. Finally, an adjustment is made to the estimated significance level to account for multiple hypotheses testing. GSEA normalizes the enrichment score for each gene set to account for the variation in set sizes, yielding a NES and a FDR. The FDR gives an estimate of the probability that a set with a given NES represents a false-positive finding; it is computed by comparing the tails of the observed and permutation-computed null distributions for the NES. The collection of gene sets used in the analysis of Fig. 3a consisted of release 2.5 of the C2 (curated gene sets) sub-collection of the Molecular Signatures Database (http:// www.broad.mit.edu/gsea/msigdb/). To determine the significance of identifying many NF-kB upregulated gene sets enriched in AALE-K cells, we used a hypergeometric test.
Gene expression profiling was also performed in triplicate in AALE-K cells (KRAS(G13D)) 5 passages after stable integration of the KRAS allele and compared with AALE-V cells using human U133A Arrays (Affymetrix). We created a new KRAS-specific gene signature using the mean difference in expression between AALE-K and AALE-V triplicate samples to determine the 300 most significantly induced genes by oncogenic KRAS. In parallel, expression profiling was performed in AALE-K cells 48 h after expression of GFP shRNA or TBK1 shRNA, to identify which of these genes were most significantly downregulated after TBK1 suppression. Signature projection method. The RAS oncogenic signature 12 , AALE-K signature, NF-kB signature 13 , IKKe-regulated NF-kB gene set 14 and IRF3 target gene set 17 were projected across 38 lung adenocarcinomas derived from the doi:10.1038/nature08460
